Drug Profile
Research programme: ras Gene inhibitors - Avantogen Oncology
Alternative Names: BIO-139Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator Avantogen Oncology
- Class
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
- 30 May 2006 Innovate Oncology has been acquired by Avantogen
- 16 Sep 2005 Preclinical trials in Cancer in USA (unspecified route)